What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Parvus pMHC nanomedicines are being developed for the treatment of autoimmune diseases. They consist of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be…”In the company’s words, NCT07423000 on ClinicalTrials.gov
- Tested for
- Inflammatory Bowel Disease (IBD)
- Main trialPhase 1
- “The goal of this clinical trial is to learn what happens to PVT401 when it enters the human body and how it affects the immune system. It will also provide information about the safety of PVT401 after a single dose and after multiple doses. The main questions it aims to answer are: Will participants experience any side effects when taking PVT401? How long does it take PVT401 to leave the body after it is administered? Healthy volunteers will participate in either the single ascending dose (SAD) or multiple ascending dose (MAD) phase. In the SAD phase, participants will: stay in the clinic…”In the company’s words, NCT07423000 on ClinicalTrials.gov
- Other names
- Parvus pMHC nanomedicine
Other drugs for Inflammatory Bowel Disease (IBD)
- ObefazimodAbivax S.A. · Phase 3
- TofacitinibPfizer · Phase 3
- RisankizumabAbbVie · Phase 3
- UpadacitinibAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
Coming up1
- Nov 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Nov 2027 | A Phase 1 Study of PVT401 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026